Clinical Core

核心B：临床项目总结 核心B：临床招募、评估和跟踪骑士ADRC队列中的所有参与者。它用得很好- 在进入时建立以线人为基础的临床和心理测量仪器(包括统一数据集) 并在此后每年获取临床、认知、行为和神经学数据，以仔细描述 每个参与者关于痴呆症的存在或不存在，以及当存在时，其严重性和病因。这个 CORE已成功地服务于骑士ADRC和 其附属赠款自1985年成立以来一直如此，并将在下一个5年供资期内继续这样做。这个 CORE在拟议的资助期内的具体目标是： 1.保持当前活跃的参与者队列(当前N=272)，仔细描述其存在的特征 或无症状性AD，以支持对临床、认知和生物医学的纵向研究 症状性阿尔茨海默病与认知正常衰老的相关性及标志 临床前阿尔茨海默病患者的认知障碍。 2.每年招募和评估40名65岁或以上(有症状的人为50岁或以上)的新参与者， 以补充自然减损，并将活跃队列扩大到约350人。 3.从以下位置收集数据、图像和生物标本(DNA、脑脊液、血浆、皮肤成纤维细胞和IPSCs) 参加者视情况而定。 4.要求所有参与者进行脑部尸检。 5.继续与圣路易斯非裔美国人社区中的个人接触，以促进将 研究中的非裔美国人。 6.结合研究教育部分，使用核心资源进行早期培训 痴呆症评估、ADRD的异质性和临床病理相关性的研究人员 探索AD的多因素性质。 7.继续确保广泛共享骑士民主与和解委员会的工具、数据和生物武器，并继续 对多中心ADRD项目的贡献。 8.阐述与认知数据、纵向分子表型、性别有关的适当的国家适应行动方案里程碑 以及种族差异、睡眠和血管对痴呆症的影响。

Core B: Clinical Project Summary Core B: Clinical recruits, assesses, and follows all participants in the Knight ADRC Cohort. It uses well- established informant-based clinical and psychometric instruments (including the Uniform Data Set) at entry and annually thereafter to obtain clinical, cognitive, behavioral, and neurological data to carefully characterize each participant as to the presence or absence of dementia and, when present, its severity and etiology. The Core has successfully functioned to serve the needs of cutting-edge research projects of the Knight ADRC and its affiliated grants since its inception in 1985 and will continue to do so in the next 5-year funding period. The Core's Specific Aims in the proposed funding period are: 1. Maintain an current active cohort of participants (current N=272), carefully characterized as to the presence or absence of symptomatic AD, to support longitudinal studies of the clinical, cognitive, and biomedical correlates of symptomatic AD in comparison with cognitively normal aging and to mark the transition of participants with preclinical AD to cognitive impairment. 2. Annually enroll and assess 40 new participants age 65y or older (50y or older for symptomatic individuals), to replenish attritional losses and expand the active cohort to ~350. 3. Collect data, images, and biospecimens (DNA, CSF, plasma, dermal fibroblasts, and iPSCs) from participants as appropriate. 4. Solicit brain autopsy from all participants. 5. Continue to engage individuals in the African American community in St. Louis to promote the inclusion of African Americans in research. 6. In conjunction with the Research Education Component, use Core resources to train early stage investigators in dementia assessment, the heterogeneity of ADRD, and clinicopathological correlations that explore the multifactorial nature of AD. 7. Continue to ensure the broad sharing of Knight ADRC tools, data, and biospecimens and continue contributions to multicenter ADRD programs. 8. Address appropriate NAPA milestones related to cognitive data, longitudinal molecular phenotyping, sex and racial differences, sleep, and vascular contributions to dementia.